Clinical Trial Update: A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC [Phase 2]

View source ↗

Summary

This document reports a Phase II clinical trial evaluating AK112, a PD-1/VEGF bispecific, in combination with chemotherapy for non-small cell lung cancer, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AK112

Snippet

Sponsor: Sichuan University | Conditions: Lung Cancer, Non-Small Cell | Phase 2 | Status: RECRUITING